FDC Limited — Important, 18-12-2024: Updates

FDC Limited has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets at its Baddi manufacturing facility. This approval not only validates the company’s compliance with stringent regulatory standards but also opens up opportunities for enhanced product offerings in the pharmaceutical market. The successful completion of this regulatory process may lead to increased revenue from this key product line. Investors should watch closely for potential growth driven by new market opportunities and the expansion of the company’s product portfolio.